1. Introduction {#sec1-medicines-07-00001}
===============

Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL), accounting for approximately half of all primary cutaneous lymphomas \[[@B1-medicines-07-00001]\]. Although the incidence of CTCL was rising in the 1970s, (due to either a real increase in cases, improvement in diagnostic methods, or a combination of the two) it has since stabilized to 5.6 per million persons with MF in the United States \[[@B2-medicines-07-00001],[@B3-medicines-07-00001],[@B4-medicines-07-00001]\].

While most commonly observed after the age of 55 years, MF onset can arise in early adulthood or childhood with a nearly 2:1 male to female ratio \[[@B2-medicines-07-00001]\]. MF typically has a slow and progressive disease course with patches, plaques and tumors developing sequentially. However, nearly 30% of patients demonstrate erythroderma or skin tumors at the outset \[[@B2-medicines-07-00001]\]. Advanced disease involving blood, lymph nodes and visceral organs occurs in close to a third of cases \[[@B1-medicines-07-00001]\]. Moreover, patients with MF are reported to be at an increased risk of developing secondary neoplasms, particularly Hodgkin lymphoma and lymphomatoid papulosis \[[@B2-medicines-07-00001]\].

Recent evidence points to a relationship with inflammatory disorders like psoriasis---attributable to similarities in pathogenesis and the possible role of Toll-like receptors in both \[[@B5-medicines-07-00001],[@B6-medicines-07-00001]\]. Patients with MF experience increased rates of cardiovascular risk factors \[[@B7-medicines-07-00001]\], and apart from those experiencing limited plaque/patch stage (T1) MF, lower overall survival when compared to healthy controls matched for race, age and sex \[[@B8-medicines-07-00001],[@B9-medicines-07-00001]\]. Being a chronic relapsing disease, the presence of comorbid conditions can potentially add to patient burden.

Considering these new observations, further investigation to elucidate the comorbidities and risk of selected malignancies associated with MF is important. To help identify the common illnesses associated with MF, a cross sectional study was conducted to evaluate 580 adult patients with diagnosed MF.

2. Materials and Methods {#sec2-medicines-07-00001}
========================

We performed a cross-sectional study of patients age 18 and older treated at Johns Hopkins Hospital System (JHHS) between January 1, 2013 and January 1, 2019. Johns Hopkins is a tertiary care referral center with a diverse catchment area which includes local, regional, national and international patients. Anonymous aggregate-level data was collected therefore institutional review board approval was waved. Lifetime incidences of comorbidities were collected using the electronic medical records system EPIC \[[@B10-medicines-07-00001],[@B11-medicines-07-00001],[@B12-medicines-07-00001]\].

Patients diagnosed with MF were compared with three groups: all adults who presented to JHHS with diagnoses other than MF (labelled "general population" for the purpose of this study), adult patients with a diagnosis of atopic dermatitis (AD) and adults diagnosed with psoriasis. The list of comorbidities was obtained from the 2015 Medicare report of the most common chronic medical illnesses affecting the United States population \[[@B13-medicines-07-00001]\]. Malignancies previously reported or suspected to be associated with MF such as Hodgkin's disease, malignant melanoma and cancers of the lung, breast or colon, were also included for analysis.

Odds ratios, *p*-values and 95% confidence intervals were calculated using chi-squared statistics with one degree of freedom. *p*-values for comparisons of odds ratios were calculated with Z-tests. A Bonferroni-corrected *p*-value of \<0.001 was applied to all assessments of statistical significance. Additionally, subgroup analyses stratified by race were performed for the aforementioned comorbidities and malignancies.

3. Results {#sec3-medicines-07-00001}
==========

Of the 4,944,449 patients that presented to JHHS in the past six years, 580 were diagnosed with MF. Of these, 56.1% were Caucasian, 32.4% were African American and 2.9% were Asian. ([Figure 1](#medicines-07-00001-f001){ref-type="fig"}) Overall, the majority (45.1%) of the MF patients were between the ages of 60 to 79 years. However, the African American MF patients were, on average, younger than the Caucasian group---47.9% of the African Americans belonged to the 50 to 69-year group while 50.1% of Caucasians belonged to the 60 to 79-year group ([Figure 2](#medicines-07-00001-f002){ref-type="fig"}).

Overall (inclusive of all races), MF was statistically significantly associated with certain cutaneous and systemic conditions when compared with all three groups---the general population, patients with AD and patients diagnosed with psoriasis. These included major depressive disorder, Hodgkin's disease, lymphomatoid papulosis (*p* \< 0.001 vs. all control groups). Patients with MF were also significantly less likely to have vitamin D deficiency (*p* \< 0.001 vs. all control groups) ([Table A1](#medicines-07-00001-t0A1){ref-type="table"}).

However, on stratifying by race there were important differences in the associated comorbidities. Among the Caucasian study group there was a statistically significant association with lymphomatoid papulosis (*p* \< 0.001 vs. all control groups). However, no instances of lymphomatoid papulosis were observed among African American patients with MF. Additionally, on racial sub stratification the association with some conditions was lost; these included congestive heart failure and atopic dermatitis ([Table A2](#medicines-07-00001-t0A2){ref-type="table"} and [Table A3](#medicines-07-00001-t0A3){ref-type="table"}).

Compared with psoriasis, MF was not associated with chronic obstructive pulmonary disease (COPD), ischemic heart disease, atrial fibrillation, allergic contact dermatitis, venous thrombosis, chronic kidney disease, malignant melanoma or Alzheimer's disease. Compared with AD, MF was not associated with osteoarthritis, rheumatoid arthritis, hyperlipidemia, diabetes mellitus type 2 and psoriasis. There was no association found with chronic hepatitis C, inflammatory bowel disease, HIV, Autistic disorder, schizophrenia, ischemic stroke and lung, breast or colon cancer on comparison with AD, psoriasis and/or the general population. The number of Asian patients in our MF cohort was too small to determine associated conditions ([Table A2](#medicines-07-00001-t0A2){ref-type="table"} and [Table A3](#medicines-07-00001-t0A3){ref-type="table"}).

4. Discussion {#sec4-medicines-07-00001}
=============

This study is among the few analyses of dermatoses, malignancies and comorbidities associated with MF. In line with the literature, the majority (64.8%) of our study group were aged between 50 and 79 years \[[@B2-medicines-07-00001],[@B3-medicines-07-00001]\]. However, in contrast to previous studies the number of females in our MF cohort outnumbered the males (51% vs. 49%) \[[@B2-medicines-07-00001],[@B3-medicines-07-00001],[@B14-medicines-07-00001],[@B15-medicines-07-00001],[@B16-medicines-07-00001]\]. Concordant with earlier observations, we found that Caucasians were most commonly affected, constituting 56.1% of our patient cohort \[[@B2-medicines-07-00001],[@B8-medicines-07-00001],[@B17-medicines-07-00001]\]. However, African Americans were disproportionately affected as compared to the general population; about 32.4% of the patients diagnosed with MF in our study were African American, whereas only 21.3% of all patients seen at JHHS over the same six-year period were African American ([Figure 1](#medicines-07-00001-f001){ref-type="fig"}). Indeed, some earlier studies have found higher incidence rates of MF in African Americans than Caucasians \[[@B3-medicines-07-00001],[@B18-medicines-07-00001],[@B19-medicines-07-00001]\]. Our African American cohort also tended to be younger than the Caucasian group ([Figure 2](#medicines-07-00001-f002){ref-type="fig"}). These are similar to the observations of Huang et al. and are important since African Americans with MF have been found to have significantly shorter overall survival when compared with age at onset-, stage- and treatment-matched Caucasian patients \[[@B17-medicines-07-00001],[@B20-medicines-07-00001]\].

Our study found that MF in Caucasian patients is statistically significantly associated with lymphomatoid papulosis, a finding that was not seen in our African American cohort. White patients with MF were 2147.0 times more likely to have lymphomatoid papulosis than Caucasians in the general population (odds ratio (OR) 2147.0; 95% CI 1062.6--4338.1) and 47.5 times more likely to have lymphomatoid papulosis than race-matched atopic dermatitis patients (OR 47.5; 95% CI 13.0--173.3) ([Table A2](#medicines-07-00001-t0A2){ref-type="table"} and [Table A3](#medicines-07-00001-t0A3){ref-type="table"}). Although, the association of MF with lymphomatoid papulosis is well known, this racial difference is significant \[[@B21-medicines-07-00001]\]. In both our African American as well as our Caucasian study groups, MF disease was found to be statistically significantly associated with Hodgkin's disease. This confirms reports of previous studies that found an association between MF and neoplastic disorders like lymphomatoid papulosis and Hodgkin's disease \[[@B22-medicines-07-00001],[@B23-medicines-07-00001],[@B24-medicines-07-00001],[@B25-medicines-07-00001],[@B26-medicines-07-00001]\]. The possible reasons for an increased risk of developing second malignancies in MF patients could either be due to the treatment used or similar dysfunctional immune surveillance leading to clonal proliferation \[[@B24-medicines-07-00001],[@B27-medicines-07-00001],[@B28-medicines-07-00001]\]. Alternatively, the two neoplasms may have common genetic events and originator cells contributing to the development of different clones \[[@B26-medicines-07-00001]\]. Considering the high odds of lymphomatoid papulosis and Hodgkin's disease being associated with MF, long term monitoring of MF patients is prudent regardless of the treatment protocol used. However, the significant racial difference observed suggest monitoring for development of MF may be more beneficial in Caucasian compared to African American patients with lymphomatoid papulosis.

Whether atopic dermatitis contributes to the development of MF has remained controversial. Results from previous studies have indicated a modest increase in the risk of lymphoma in patients with AD \[[@B11-medicines-07-00001]\]. We found that overall (inclusive of all races), patients with MF were not significantly more likely to have AD when compared with patients with psoriasis (*p* = 0.022). Moreover, this was corroborated when racial sub-group analysis was performed. One possible explanation for the observations in earlier studies is early misclassification of some MF cases as AD. Due to similarities in clinical presentation, there can be a delay from the date of presentation to the diagnosis of MF. A recent study observed higher rates of pruritus associated with malignancies, particularly in case of cutaneous lymphoma in blacks which may add to the difficulty in initial diagnosis \[[@B29-medicines-07-00001]\]. Also, often long term or treatment refractory cases labelled AD may get re-biopsied and demonstrate MF.

A recent retrospective analysis demonstrated that about 12.7% (41 of 321) of the MF patients had associated psoriasis; of these, 20 patients had psoriasis coexistent with MF. The authors of this study suggested that this association was less likely due to misclassification and could be due to the underlying abnormal T-cell activation in psoriasis which can potentially contribute to the development of cancer \[[@B5-medicines-07-00001]\]. However, contrary to their observations, we found that when compared with patients with AD, MF patients were not significantly more likely to have psoriasis (OR 1.1; CI 0.7--1.7; *p* = 0.6), suggesting that misclassification contributes to an inflated number of psoriasis cases thought to be associated with MF. Nevertheless, further investigation into this may be warranted.

Vitamin D deficiency has earlier been thought to play a role in triggering MF \[[@B30-medicines-07-00001]\]. In contrast, our study found that MF patients (all races) were 4.6 times (*p* \< 0.001) significantly less likely to have vitamin D deficiency than the general population. This is maintained on subgroup analysis: Caucasian MF patients were significantly less likely to have concomitant vitamin D deficiency compared with AD, psoriasis and general population (*p* \< 0.001). Our African American cohort was also significantly less likely to have vitamin D deficiency when compared with the general population ([Table A2](#medicines-07-00001-t0A2){ref-type="table"}). These observations diverge from that of Talpur et al. who found about 77% of their CTCL patients to be deficient in vitamin D deficiency \[[@B31-medicines-07-00001]\]. One rationale could be the use of phototherapy which may have led to improved vitamin D levels in our cohort, however, further longitudinal studies may be required for confirmation.

Interestingly, our data identified a statistically significant association with congestive heart failure, compared with the general population and AD. This association was maintained on sub stratification by race---both Caucasian and African American patients had a significant association with congestive heart failure. Also, there was a significant association with important coronary artery disease (CAD) risk factors, hypertension and hyperlipidemia (OR 5.3 and 5.0, respectively; *p* \< 0.001), when compared with the general population. The association was comparable on racial sub-group analysis ([Table A1](#medicines-07-00001-t0A1){ref-type="table"}, [Table A2](#medicines-07-00001-t0A2){ref-type="table"} and [Table A3](#medicines-07-00001-t0A3){ref-type="table"}). A possible explanation for this could be that acquired cardiovascular diseases as well as common coronary artery disease (CAD) risk factors (hypertension and hyperlipidemia) are more frequent beyond middle age which is the most commonly affected age group in MF \[[@B32-medicines-07-00001]\]. However, Cengiz et al. recently demonstrated an increased rate of cardiovascular risk factors (hyperlipidemia, high homocysteine and high-sensitivity C-reactive protein) in a cohort of MF patients who did not have pre-existing metabolic disease and were lifetime non-smokers, suggesting a real increase in cardiovascular morbidity by virtue of MF \[[@B7-medicines-07-00001]\]. This begs the chicken or the egg dilemma: are these patients at risk for developing the risk factors for cardiovascular disease (CVD), or do they also have an increased risk of CVD independent of known changes in risk factors or perhaps MF exacerbates risk factors. Further examination of cardiovascular disease and CAD risk factors in MF is suggested by these findings. However, when compared with psoriasis the association of MF with important CAD risk factors, hypertension and hyperlipidemia, was significantly less likely (*p* \< 0.001). This held true for all sub-group analyses except in the case of hyperlipidemia in African Americans ([Table A1](#medicines-07-00001-t0A1){ref-type="table"}, [Table A2](#medicines-07-00001-t0A2){ref-type="table"} and [Table A3](#medicines-07-00001-t0A3){ref-type="table"}).

Our study has several limitations. First, its cross-sectional design prohibits determining a temporal relationship. The data was representative of the population seen at a single tertiary care hospital system in the United States and thus, may not be generalizable. Also, misclassification of early MF as morphologically similar dermatoses like atopic dermatitis, contact dermatitis and psoriasis is possible and could potentially contribute to an inflated percentage of these dermatoses showing up in our results. Additionally, the comparison group "general population" in our study refers to the total population excluding patients with MF, however, since patients with AD and psoriasis are included in this group it may lead to an overestimation or underestimation of results. Moreover, as aggregate level data was used, gender information missing at the time of analysis may account for our unexpected sex distribution. Finally, there may be additional unknown confounding factors such as socioeconomic status or preexisting medical comorbidities in the mycosis fungoides group that could have affected the interpretation of our results.

5. Conclusions {#sec5-medicines-07-00001}
==============

These results indicate that MF is strongly associated with Hodgkin's disease, and that MF in Caucasians is associated with lymphomatoid papulosis. This finding in this study suggests that clinicians consider long term follow up for Caucasian but not African American patients with lymphomatoid papulosis to monitor for development of MF. Moreover, we found that although MF is significantly associated with CAD risk factors compared with the general population, these associations were less likely on comparison with psoriasis. On comparison with clinical mimickers, MF was not significantly associated with contact dermatitis (compared with psoriasis) and psoriasis (compared with AD) or lung, breast and colon cancer, conditions that have previously been thought to be associated with MF.
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medicines-07-00001-t0A1_Table A1

###### 

Absolute number, percentage, odds ratios and *p* values of all patients 18 years and older with MF and various comorbid conditions, as compared with those of patients 18 and older with AD, with psoriasis, or within the general population (without MF) who were seen at the Johns Hopkins Hospital System (JHHS) between January 1, 2013 and January 1, 2019. Data presented for 580 patients with mycosis fungoides (MF), 10,382 patients with AD, 15,051 patients with psoriasis, and 4,943,869 patients in the general population (excluding those with MF). AD, Atopic dermatitis; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PN, prurigo nodularis.

  Comorbidity                   MF, n (%)    AD, n (%)     OR (95% CI)        *p* Value   Psoriasis, n (%)   OR (95% CI)       *p* Value   Gen Pop, n (%)   OR (95% CI)               *p* Value
  ----------------------------- ------------ ------------- ------------------ ----------- ------------------ ----------------- ----------- ---------------- ------------------------- -----------
  Allergic Contact Dermatitis   6 (1.0)      428 (4.1)     0.2 (0.1--0.5)     \<0.001     137 (0.9)          1.1 (0.5--2.6)    0.75779     4876 (0.1)       10.6 (4.7--23.7)          \<0.001
  Alzheimer Disease             5 (0.9)      27 (0.3)      3.3 (1.3--8.7)     0.00892     105 (0.7)          1.2 (0.5--3.0)    0.64202     8882 (0.2)       4.8 (2.0--11.7)           \<0.001
  Asthma                        38 (6.6)     2223 (21.4)   0.3 (0.2--0.4)     \<0.001     1529 (10.2)        0.6 (0.4--0.9)    0.00454     109,109 (2.2)    3.1 (2.2--4.3)            \<0.001
  Atopic Dermatitis             23 (4.0)                                                  369 (2.5)          1.6 (1.1--2.5)    0.02214     10,358 (0.2)     19.7 (13.0--29.9)         \<0.001
  Atrial Fibrillation           32 (5.5)     284 (2.7)     2.1 (1.4--3.0)     \<0.001     931 (6.2)          0.9 (0.6--1.3)    0.51122     68,394 (1.4)     4.2 (2.9--5.9)            \<0.001
  Autistic Disorder             0 (0)        50 (0.5)      0                  0.09391     19 (0.1)           0                 0.39189     2371 (0.0)       0                         0.59782
  Breast Cancer                 2 (0.3)      33 (0.3)      1.1 (0.3--4.5)     0.91079     76 (0.5)           0.7 (0.2--2.8)    0.59126     7509 (0.2)       2.3 (0.6--9.1)            0.23285
  Chronic Hepatitis C           3 (0.5)      130 (1.3)     0.4 (0.1--1.3)     0.11564     214 (1.4)          0.4 (0.1--1.1)    0.06769     13,952 (0.3)     1.8 (0.6--5.7)            0.28601
  Chronic Kidney Disease        41 (7.1)     446 (4.3)     1.7 (1.2--2.4)     0.00161     950 (6.3)          1.1 (0.8--1.6)    0.46281     57,386 (1.2)     6.5 (4.7--8.9)            \<0.001
  Colon Cancer                  0 (0)        8 (0.1)       0                  0.50364     27 (0.2)           0                 0.3073      2561 (0.1)       0                         0.5835
  Congestive Heart Failure      37 (6.4)     287 (2.8)     2.4 (1.7--3.4)     \<0.001     675 (4.5)          1.5 (1.0--2.0)    0.03177     43,133 (0.9)     7.7 (5.5--10.8)           \<0.001
  COPD                          36 (6.2)     424 (4.1)     1.6 (1.1--2.2)     0.01308     961 (6.4)          1.0 (0.7--1.4)    0.86328     51,410 (1.0)     6.3 (4.5--8.8)            \<0.001
  Diabetes Mellitus Type 2      64 (11.0)    103 (9.7)     1.2 (0.9--1.5)     0.27746     2191 (14.6)        0.7 (0.6--0.9)    0.01782     136,538 (2.8)    4.4 (3.4--5.7)            \<0.001
  HIV                           3 (0.5)      185 (1.8)     0.3 (0.1--0.9)     0.02243     144 (1.0)          0.5 (0.4--0.7)    0.28188     13,283 (0.3)     1.9 (0.6--6.0)            0.24755
  Hodgkin's Disease             7 (1.2)      10 (0.1)      12.7 (4.8--33.4)   \<0.001     20 (0.1)           9.2 (3.9--21.8)   \<0.001     1631 (0.0)       37.0 (17.5--78.1)         \<0.001
  Hyperlipidemia                155 (26.7)   2736 (26.4)   1.0 (0.8--1.2)     0.84364     5,812 (38.6)       0.6 (0.5--0.7)    \<0.001     335,534 (6.8)    5.0 (4.2--6.0)            \<0.001
  Hypertension                  194 (33.4)   2991 (28.8)   1.2 (1.0--1.5)     0.01664     6128 (40.7)        0.7 (0.6--0.9)    \<0.001     427,318 (8.6)    5.3 (4.5--6.3)            \<0.001
  Inflammatory Bowel Disease    5 (0.9)      94 (0.9)      1.0 (0.4--2.3)     0.91448     228 (1.5)          0.6 (0.2--1.4)    0.203       8817 (0.2)       4.9 (2.0--11.7)           \<0.001
  Ischemic Heart Disease        53 (9.1)     512 (4.9)     1.9 (1.4--2.6)     \<0.001     1274 (8.5)         1.1 (0.8--1.5)    0.56805     79,665 (1.6)     6.1 (4.6--8.1)            \<0.001
  Ischemic Stroke               0 (0)        23 (0.2)      0                  0.25649     37 (0.2)           0                 0.23189     2715 (0.1)       0                         0.5724
  Lung Cancer                   3 (0.5)      30 (0.3)      1.8 (0.5--5.9)     0.32876     83 (0.6)           0.9 (0.3--3.0)    0.91295     7229 (0.1)       3.6 (1.1--11.0)           0.01939
  Lymphomatoid Papulosis        11 (1.9)     4 (0.0)       50.2 (15.9--158)   \<0.001     \-                 0                 \<0.001     49 (0.0)         1950.5 (1009.0--3770.4)   \<0.001
  Major Depressive Disorder     44 (7.6)     1340 (12.9)   0.6 (0.4--0.8)     \<0.001     2091 (13.9)        0.5 (0.4--0.7)    \<0.001     119,308 (2.4)    3.3 (2.4--4.5)            \<0.001
  Malignant Melanoma            9 (1.6)      70 (0.7)      2.3 (1.2--4.7)     0.01504     164 (1.1)          1.4 (0.7--2.8)    0.29657     7879 (0.2)       9.9 (5.1--19.1)           \<0.001
  Osteoarthritis                80 (13.8)    1689 (16.3)   0.8 (0.6--1.0)     0.11477     3981 (26.5)        0.4 (0.4--0.6)    \<0.001     187,109 (3.8)    4.1 (3.2--5.2)            \<0.001
  Osteoporosis                  13 (2.2)     417 (4.0)     0.5 (0.3--1.0)     0.0321      870 (5.8)          0.4 (0.2--0.7)    \<0.001     44,238 (0.9)     2.5 (1.4--4.4)            \<0.001
  Psoriasis                     23 (4.0)     369 (3.6)     1.1 (0.7--1.7)     0.60368                                                      15,028 (0.3)     13.5 (8.9--20.6)          \<0.001
  Rheumatoid Arthritis          8 (1.4)      128 (1.2)     1.1 (0.5--2.3)     0.75656     493 (3.3)          0.4 (0.2--0.8)    0.01095     11,071 (0.2)     6.2 (3.1--12.5)           \<0.001
  Schizophrenia                 2 (0.3)      73 (0.7)      0.5 (0.1--2.0)     0.30831     71 (0.5)           0.7 (0.2--3.0)    0.66003     8507 (0.2)       2.0 (0.5--8.0)            0.31551
  Venous Thrombosis             26 (4.5)     268 (2.6)     1.8 (1.2-2.7)      0.00581     496 (3.3)          1.4 (0.9-2.1)     0.11836     34,113 (0.7)     6.8 (4.6--10.0)           \<0.001
  Vitamin D Deficiency          65 (11.2)    2052 (19.8)   0.5 (0.4--0.7)     \<0.001     2996 (19.9)        0.5 (0.4--0.7)    \<0.001     132,446 (2.7)    4.6 (3.5--5.9)            \<0.001

medicines-07-00001-t0A2_Table A2

###### 

Absolute number, percentage, odds ratios and *p* values of Black/African American patients age 18 years and older with mycosis fungoides and various comorbid conditions, as compared with race-matched controls age 18 years and older with AD, with psoriasis, or within the general population who were seen at the JHHS between January 1, 2013 and January 1, 2019. Data presented for 190 patients with mycosis fungoides (MF), 4287 patients with AD, 1690 patients with psoriasis, and 944,278 patients in the general population (excluding those with MF). AD, Atopic dermatitis; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PN, prurigo nodularis; IBS, inflammatory bowel disease.

  Comorbidity                   MF, n (%)   AD, n (%)     OR (95% CI)         *p* Value   Psoriasis, n (%)   OR (95% CI)       *p* Value   Gen Pop, n (%)   OR (95% CI)         *p* Value
  ----------------------------- ----------- ------------- ------------------- ----------- ------------------ ----------------- ----------- ---------------- ------------------- -----------
  Allergic Contact Dermatitis   2 (1.1)     118 (2.8)     0.4 (0.1--1.5)      0.15571     22 (1.3)           0.8 (0.2--3.5)    0.77179     893 (0.1)        11.2 (2.8--45.3)    \<0.001
  Alzheimer Disease             2 (1.1)     10 (0.2)      4.6 (1.0--20.9)     0.03255     11 (0.7)           1.6 (0.4--7.4)    0.52635     1742 (0.2)       5.8 (1.4--23.2)     0.00532
  Asthma                        18 (9.5)    1240 (28.9)   0.3 (0.2--0.4)      \<0.001     266 (15.7)         0.6 (0.3--0.9)    0.02221     40,063 (4.2)     2.4 (1.4--3.8)      \<0.001
  Atopic Dermatitis             11 (5.8)                                                  93 (5.5)           1.1 (0.6--2.0)    0.86989     4276 (0.5)       13.5 (7.3--24.9)    \<0.001
  Atrial Fibrillation           13 (6.8)    74 (1.7)      4.2 (2.3--7.7)      \<0.001     75 (4.4)           1.6 (0.9--2.9)    0.13687     10,168 (1.1)     6.7 (3.8--11.9)     \<0.001
  Autistic Disorder                         17 (0.4)      0                   0.38448     6 (0.4)            0                 0.41072     687 (0.1)        0                   0.70994
  Breast Cancer                 2 (1.1)     13 (0.3)      3.5 (0.8--15.6)     0.08025     10 (0.6)           1.8 (0.4--8.2)    0.44942     1465 (0.2)       6.8 (1.7--27.6)     0.00168
  Chronic Hepatitis C           2 (1.1)     95 (2.2)      0.5 (0.1--1.9)      0.28112     64 (3.8)           0.3 (0.1--1.1)    0.05218     7057 (0.7)       1.4 (0.4--5.7)      0.62517
  Chronic Kidney Disease        18 (9.5)    224 (5.2)     1.9 (1.1--3.1)      0.01127     179 (10.6)         0.9 (0.5--1.5)    0.63332     20,616 (2.2)     4.7 (2.9--7.6)      \<0.001
  Colon Cancer                              1 (0.0)       0                   0.83324     2 (0.1)            0                 0.63519     461 (0.0)        0                   0.76064
  Congestive Heart Failure      17 (8.9)    136 (3.2)     3.0 (1.8--5.1)      \<0.001     115 (6.8)          1.3 (0.8--2.3)    0.2731      13,103 (1.4)     7.0 (4.2--11.5)     \<0.001
  COPD                          13 (6.8)    195 (4.5)     1.5 (0.9--2.8)      0.14163     120 (7.1)          1.0 (0.5--1.7)    0.89518     13,161 (1.4)     5.2 (3.0--9.1)      \<0.001
  Diabetes Mellitus Type 2      34 (17.9)   525 (12.2)    1.6 (1.1--2.3)      0.02118     379 (22.4)         0.8 (0.5--1.1)    0.15263     47,086 (50.)     4.2 (2.9--6.0)      \<0.001
  HIV                           3 (1.6)     158 (3.7)     0.4 (0.1--1.3)      0.12699     75 (4.4)           0.3 (0.1--1.1)    0.06099     8937 (0.9)       1.7 (0.5--5.3)      0.36796
  Hodgkin's Disease             2 (1.1)     2 (0.0)       22.8 (3.2--162.7)   \<0.001     2 (0.1)            9.0 (1.3--64.1)   0.00805     273 (0.0)        36.8 (9.1--148.9)   \<0.001
  Hyperlipidemia                48 (25.3)   961 (22.4)    1.2 (0.8--1.6)      0.35813     632 (37.4)         0.6 (0.4--0.8)    \<0.001     72,033 (7.6)     4.1 (3.0--5.7)      \<0.001
  Hypertension                  81 (42.6)   1333 (31.1)   1.6 (1.2--2.2)      \<0.001     884 (52.3)         0.7 (0.5--0.9)    0.01141     127,879 (13.5)   4.7 (3.6--6.3)      \<0.001
  IBS                           2 (1.1)     28 (0.7)      1.6 (0.4--6.8)      0.50894     18 (1.1)           1.0 (0.2--4.3)    0.98734     1363 (0.1)       7.4 (1.8--29.7)     \<0.001
  Ischemic Heart Disease        20 (10.5)   243 (5.7)     2.0 (1.2--3.2)      0.00533     183 (10.8)         1.0 (0.6--1.6)    0.89878     21,833 (2.3)     5.0 (3.1--7.9)      \<0.001
  Ischemic Stroke                           7 (0.2)       0                   0.57723     6 (0.4)            0                 0.41072     847 (0.1)        0                   0.6796
  Lung Cancer                   1 (0.5)     8 (0.2)       2.8 (0.4--22.7)     0.30631     14 (0.8)           0.6 (0.1--4.8)    0.65722     1321 (0.1)       3.8 (0.5--27.0)     0.15429
  Lymphomatoid Papulosis                    1 (0.0)       0                   0.83324                                                      7 (0.0)          0                   0.97006
  Major Depressive Disorder     18 (9.5)    615 (14.3)    0.6 (0.4--1.0)      0.05928     265 (15.7)         0.6 (0.3--0.9)    0.0233      29,514 (3.1)     3.2 (2.0--5.3)      \<0.001
  Malignant Melanoma                        3 (0.1)       0                   0.71529                                                      177 (0.0)        0                   0.8503
  Osteoarthritis                28 (14.7)   643 (15.0)    1.0 (0.7--1.5)      0.92114     433 (25.6)         0.5 (0.3--0.8)    \<0.001     44,608 (4.7)     3.5 (2.3--5.2)      \<0.001
  Osteoporosis                  2 (1.1)     83 (1.9)      0.5 (0.1--2.2)      0.38258     75 (4.4)           0.2 (0.1--0.9)    0.0256      5538 (0.6)       1.8 (0.4--7.3)      0.40015
  Psoriasis                     9 (4.7)     93 (2.2)      2.2 (1.1--4.5)      0.02029                                                      1681 (0.2)       27.9 (14.2--54.5)   \<0.001
  Rheumatoid Arthritis          3 (1.6)     54 (1.3)      1.3 (0.4--4.1)      0.70085     60 (3.6)           0.4 (0.1--1.4)    0.15226     13,171 (1.4)     1.1 (0.4--3.5)      0.82869
  Schizophrenia                             53 (1.2)      0                   0.12313     24 (1.4)           0                 0.09829     5083 (0.5)       0                   0.31056
  Venous Thrombosis             10 (5.3)    114 (2.7)     2.0 (1.0--3.9)      0.03233     74 (4.4)           1.2 (0.6--2.4)    0.57583     9077 (1.)        5.7 (3.0--10.8)     \<0.001
  Vitamin D Deficiency          30 (15.8)   882 (20.6)    0.7 (0.5--1.1)      0.10909     433 (25.6)         0.5 (0.4--0.8)    0.00286     38,158 (4.0)     4.5 (3.0--6.6)      \<0.001
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###### 

Absolute number, percentage, odds ratios and *p* values of White/Caucasian patients age 18 years and older with mycosis fungoides (MF) and various comorbid conditions, as compared with race-matched controls age 18 years and older with AD, with psoriasis, or within the general population who were seen at the JHHS between January 1, 2013 and January 1, 2019. Data presented for 329 patients with mycosis fungoides (MF), 4545 patients with AD, 11,700 patients with psoriasis, and 2,671,135 patients in the general population (excluding those with MF). AD, Atopic dermatitis; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PN, prurigo nodularis; IBS, inflammatory bowel disease.

  Comorbidity                   MF, n (%)    AD, n (%)     OR (95% CI)         *p* Value   Psoriasis, n (%)   OR (95% CI)2      *p* Value   Gen Pop, n (%)   OR (95% CI)               *p* Value
  ----------------------------- ------------ ------------- ------------------- ----------- ------------------ ----------------- ----------- ---------------- ------------------------- -----------
  Allergic Contact Dermatitis   4 (1.2)      249 (5.5)     0.2 (0.1--0.6)      \<0.001     100 (0.9)          1.4 (0.5--3.9)    0.48534     3294 (0.1)       10.0 (3.7--26.7)          \<0.001
  Alzheimer Disease             3 (0.9)      15 (0.3)      2.8 (0.8--9.6)      0.09295     88 (0.8)           1.2 (0.4--3.9)    0.7416      6306 (0.2)       3.9 (1.2--12.1)           0.01157
  Asthma                        19 (5.8)     764 (16.8)    0.3 (0.2--0.5)      \<0.001     1138 (9.7)         0.6 (0.4--0.9)    0.01651     58,241 (2.2)     2.7(1.7--4.4)             \<0.001
  Atopic Dermatitis             11 (3.3)                                                   224 (1.9)          1.8 (1.0--3.3)    0.06476     4534 (0.2)       20.3 (11.1--37.1)         \<0.001
  Atrial Fibrillation           18 (5.5)     187 (4.1)     1.3 (0.8--2.2)      0.23646     808 (6.9)          0.8 (0.5--1.3)    0.31012     53,118 (2.0)     2.9 (1.8--4.6)            \<0.001
  Autistic Disorder                          29 (0.6)      0                   0.14617     10 (0.1)           0                 0.59577     1451 (0.1)       0                         0.67239
  Breast Cancer                              18 (0.4)      0                   0.25279     62 (0.5)           0                 0.18557     4966 (0.2)       0                         0.43374
  Chronic Hepatitis C           1 (0.3)      29 (0.6)      0.5 (0.1--3.5)      0.45432     137 (1.2)          0.3 (0.0--1.8)    0.14529     6140 (0.2)       1.3 (0.2--9.4)            0.7789
  Chronic Kidney Disease        20 (6.1)     187 (4.1)     1.5 (0.9--2.4)      0.08793     707 (6.0)          1.0 (0.6--1.6)    0.97826     31,639 (1.2)     5.4 (3.4--8.5)            \<0.001
  Colon Cancer                               4 (0.1)       0                   0.59036     23 (0.2)           0                 0.42083     1842 (0.1)       0                         0.63373
  Congestive Heart Failure      18 (5.5)     132 (2.9)     1.9 (1.2--3.2)      0.00924     518 (4.4)          1.2 (0.8--2.0)    0.3655      26,637 (1.0)     5.7 (3.6--9.2)            \<0.001
  COPD                          21 (6.4)     209 (4.6)     1.4 (0.9--2.2)      0.14046     797 (6.8)          0.9 (0.6--1.5)    0.7605      35,482 (1.3)     5.1 (3.3--7.9)            \<0.001
  Diabetes Mellitus Type 2      24 (7.3)     346 (7.6)     1.0 (0.6--1.5)      0.83347     1562 (13.4)        0.5 (0.3--0.8)    0.00137     70,060 (2.6)     2.9 (1.9--4.4)            \<0.001
  HIV                                        18 (0.4)      0                   0.25279     63 (0.5)           0                 0.18204     3463 (0.1)       0                         0.51342
  Hodgkin's Disease             4 (1.2)      5 (0.1)       11.2 (3.0--41.8)    \<0.001     16 (0.1)           9.0 (3.0--27.0)   \<0.001     1103 (0.0)       29.8 (11.1--80.0)         \<0.001
  Hyperlipidemia                99 (30.1)    1408 (31.0)   1.0 (0.8--1.2)      0.73649     4631 (39.6)        0.7 (0.5--0.8)    \<0.001     221,792 (8.3)    4.8 (3.8--6.0)            \<0.001
  Hypertension                  102 (31.0)   1337 (29.4)   1.1 (0.8--1.4)      0.5425      4733 (40.5)        0.7 (0.5--0.8)    \<0.001     251,808 (9.4)    4.3 (3.4--5.5)            \<0.001
  IBS                           2 (0.6)      50 (1.1)      0.5 (0.1--2.3)      0.40138     198 (1.7)          0.4 (0.1--1.4)    0.12925     6582 (0.2)       2.5 (0.6--9.9)            0.18606
  Ischemic Heart Disease        29 (8.8)     224 (4.9)     1.9 (1.2--2.8)      0.00215     995 (8.5)          1.0 (0.7--1.5)    0.84233     50,371 (1.9)     5.0 (3.4--7.4)            \<0.001
  Ischemic Stroke               \-           14 (0.3)      0                   0.31339     28 (0.2)           0                 0.37435     1564 (0.1)       0                         0.66064
  Lung Cancer                   2 (0.6)      16 (0.4)      1.7 (0.4--7.6)      0.46001     65 (0.6)           1.1 (0.3--4.5)    0.89987     5063 (0.2)       3.2 (0.8--12.9)           0.08111
  Lymphomatoid Papulosis        10 (3.0)     3 (0.1)       47.5 (13.0-173.3)   \<0.001                                                      39 (0.0)         2147.0 (1062.6--4338.1)   \<0.001
  Major Depressive Disorder     25 (7.6)     617 (13.6)    0.5 (0.3--0.8)      0.00197     1720 (14.7)        0.5 (0.3--0.7)    \<0.001     80,063 (3.0)     2.7 (1.8--4.0)            \<0.001
  Malignant Melanoma            9 (2.7)      65 (1.4)      1.9 (1.0--3.9)      0.0615      157 (1.3)          2.1 (1.0--4.1)    0.03259     7314 (0.3)       10.2 (3.7--26.7)          \<0.001
  Osteoarthritis                48 (14.6)    869 (19.1)    0.7 (0.5--1.0)      0.04233     3281 (28.0)        0.4 (0.3--0.6)    \<0.001     125,515 (4.7)    3.5 (2.6--4.7)            \<0.001
  Osteoporosis                  10 (3.0)     261 (5.7)     0.5 (0.3--1.0)      0.03882     729 (6.2)          0.5 (0.3--0.9)    0.01744     33,605 (1.3)     2.5 (1.3--4.6)            0.00375
  Psoriasis                     12 (3.6)     224 (4.9)     0.7 (0.4--1.3)      0.29586                                                      11,689 (0.4)     8.6 (4.8--15.3)           \<0.001
  Rheumatoid Arthritis          5 (1.5)      58 (1.3)      1.2 (0.5--3.0)      0.70559     390 (3.3)          0.4 (0.2--1.1)    0.06869     35,498 (1.3)     1.1 (0.5--2.8)            0.76249
  Schizophrenia                 2 (0.6)      16 (0.4)      1.7 (0.4--7.6)      0.46001     43 (0.4)           1.7 (0.4--6.9)    0.4812      2777 (0.1)       5.9 (1.5--23.6)           0.00458
  Venous Thrombosis             12 (3.6)     130 (2.9)     1.3 (0.7--2.3)      0.41235     403 (3.4)          1.1 (0.6--1.9)    0.84231     22,078 (0.8)     4.5 (2.6--8.1)            \<0.001
  Vitamin D Deficiency          29 (8.8)     838 (18.4)    0.4 (0.3--0.6)      \<0.001     2259 (19.3)        0.4 (0.3--0.6)    \<0.001     75,560 (2.8)     3.3 (2.3--4.9)            \<0.001

![Racial backgrounds of all patients 18 years and older with a diagnosis of mycosis fungoides (MF), atopic dermatitis (AD), or psoriasis and within the general population who presented to the Johns Hopkins Hospital System between January 1, 2013 and January 1, 2019.](medicines-07-00001-g001){#medicines-07-00001-f001}

![Age distribution of patients with mycosis fungoides (MF) overall, in black and in patients.](medicines-07-00001-g002){#medicines-07-00001-f002}

[^1]: Considered co-senior authors.
